A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

Clinical trial NCT04399837 · COMPLETED

Trial details

NCT number: NCT04399837
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Generalized Pustular Psoriasis

Start date: 2020-06-04
Primary completion: 2022-11-23
Enrollment: 123

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.